Keyphrases
Human Epidermal Growth Factor Receptor 2 (HER2)
100%
Trastuzumab
77%
Neratinib
71%
Breast Cancer
58%
Metastatic Breast Cancer
55%
HER2 mutation
39%
Tumor
34%
HER2-positive Breast Cancer
33%
Basket Study
29%
Kinase Domain
28%
Pertuzumab
28%
HER2-positive
26%
Somatic mutation
26%
Activating mutation
25%
Epidermal Growth Factor Receptor
24%
Circulating Tumor DNA (ctDNA)
24%
ErbB2
23%
T-DM1
23%
Paclitaxel
23%
Genome Sequencing
21%
Receptor Tyrosine Kinase
20%
Phosphorylation
20%
Genetic Modification
19%
Genomic Characterization
19%
HER2-targeted Therapy
19%
HER3
18%
HER4
18%
Trastuzumab Emtansine
18%
Her2neu
17%
Ceramide
17%
Confidence Interval
16%
Estrogen Receptor-positive Breast Cancer
15%
Diarrhea
15%
Cancer Genome Sequencing
15%
Targeted Therapy
14%
C-terminal Tail
14%
PIK3CA
13%
Clinical Trials
13%
Tyrosine Kinase
13%
Loperamide
12%
Capecitabine
12%
Induced Apoptosis
12%
Fulvestrant
12%
Phosphoproteomics
12%
Objective Response Rate
12%
HER2 Amplification
11%
EGF Receptor
11%
Overexpression
11%
Adjuvant Trastuzumab
11%
HER2-positive Early-stage Breast Cancer
11%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
82%
Kinase
60%
Phosphotransferase
60%
Receptor Tyrosine Kinase
47%
Genomics
43%
Somatic Mutation
30%
Clinical Trial
30%
C-Terminus
28%
Neratinib
26%
Trastuzumab
26%
Tyrosine Kinase
22%
Estrogen Receptor
21%
Phosphoproteomics
17%
Cancer Genome Sequencing
16%
Gene Amplification
15%
Tyrosine Kinase Inhibitor
14%
Tumor Suppressor Protein
14%
ErbB
14%
Conformation
12%
Lapatinib
12%
Oncogene
11%
Exome Sequencing
11%
Drug Resistance
11%
Ceramide
11%
Programmed Cell Death
11%
MAP3K1
10%
Signaling Protein
9%
Aromatase Inhibitor
9%
Colon
9%
Genome Sequencing
8%
Messenger RNA
8%
Dimerization
8%
Autophosphorylation
8%
Carcinogenesis
7%
Signal Transduction
7%
Gene Interaction
7%
GATA3
7%
Transcription
7%
Quantitative Proteomics
7%
RNA
7%
Transgenic Mouse
7%
Missense Mutation
7%
Tyrosine
7%
Loss of Function Mutation
6%
Dynamics
6%
Capecitabine
6%
Proteomics
6%
Crystal Structure
6%
N-Terminus
5%
Polymerase Chain Reaction
5%
Medicine and Dentistry
Breast Cancer
88%
Trastuzumab
62%
Metastatic Breast Cancer
44%
Neoplasm
38%
Neratinib
38%
Clinical Trial
31%
Targeted Therapy
29%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
25%
Pertuzumab
20%
Epidermal Growth Factor Receptor 2
19%
Epidermal Growth Factor Receptor
19%
Circulating Tumor DNA
19%
Estrogen Receptor Positive Breast Cancer
17%
Somatic Mutation
16%
Adverse Event
16%
Gamma Urogastrone
16%
Malignant Neoplasm
14%
Capecitabine
13%
Tyrosine-Kinase Inhibitor
12%
Paclitaxel
12%
Zirconium 89
11%
Trastuzumab Emtansine
11%
Progression Free Survival
11%
Cancer
11%
Arm
10%
DNA Sequence
10%
Hormone Therapy
10%
Diseases
10%
Lapatinib
8%
Gene Amplification
8%
Aromatase Inhibitor
8%
Genome Sequencing
8%
Adjuvant Therapy
8%
Drug Resistance
7%
Solid Malignant Neoplasm
7%
Metastatic Colorectal Cancer
7%
Disease Free Survival
7%
Molecular Profiling
7%
Recurrent Disease
7%
Lobular Carcinoma
6%
Palbociclib
6%
Colorectal Carcinoma
6%
Randomized Controlled Trial
6%
Carcinogenesis
6%
Positron Emission Tomography-Computed Tomography
6%
Biological Marker
6%
Cancer Therapy
6%
Overall Survival
6%
Quality of Life
5%
Locally Advanced Breast Cancer
5%